739 results on '"Bertilsson L"'
Search Results
52. Distribution and elimination kinetics of carbamazepine in man
53. Monoamine metabolites in cerebrospinal fluid during treatment with clonidine or alprenolol
54. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism
55. PHARMACOKINETICS OF INDOMETHACIN IN MAN
56. MONOAMINE METABOLITES IN CEREBROSPINAL FLUID IN RELATION TO DEPRESSIVE ILLNESS, SUICIDAL BEHAVIOUR AND PERSONALITY
57. Genetic Variability in Man as a Complicating Factor in the Extrapolation of Toxicological Data from Animals
58. Monoamine metabolites in cerebrospinal fluid during treatment of hypertension with prazosin
59. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine
60. Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy Swedes
61. A 5-year prospective population-based study of juvenile chronic arthritis : onset, disease process, and outcome.
62. Inhibition of debrisoquine hydroxylation with quinidine in subjects with three or more functional CYP2D6 genes
63. Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance
64. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas : relative risks and time trends in the Swedish Biologics Register
65. S.25.01 Pharmacogenetics of antidepressant, antiepileptic and neuroleptic drug treatment
66. THU0319 Disease course, outcome and predictors of outcome in an unselected cohort of individuals with juvenile chronic arthritis followed for 17 years
67. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
68. TNF-antagonist treatment and risk of hospitalisation for infection. Results from the National Swedish Monitoring-Program for Biologics in RA (ARTIS).
69. TNF-antagonist treatment and risk of hospitalisation for cardiovascular disease. Results from the National Swedish Monitoring-Program for Biologies in Ra (ARTIS).
70. Risk of tuberculosis in rheumatoid arthritis and following anti-TNF treatment. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA
71. Characteristics of malignant lymphomas following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA
72. Risk of hospitalisation for infections following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA
73. Risk of cardiovascular morbidity and mortality following TNF-blockade. Preliminary results of an ongoing Swedish monitoring-programme of biologics in RA
74. Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
75. A 5-year prospective population-based study of juvenile chronic arthritis: onset, disease process, and outcome
76. Risk for lymphomas following TNF-blockade. Comparisons with a nationwide co-morbidity database
77. Safety and efficacy of adalimumab in arthritis patients previously treated with another biologic agent
78. A national database for co-morbidity in RA to evaluate drug safety. Solid cancers in RA and following anti-TNF treatment
79. Lymphomas in RA patients treated with TNF-blockers. Cases found in a post-marketing surveillance in Sweden
80. D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate
81. Disposition of debrisoquine and nortriptyline in Korean subjects in relation to CYP2D6 genotypes, and comparison with Caucasians.
82. Individualized medicine - implementation of pharmacogenetic diagnostics in antidepressant drug treatment of major depressive disorders.
83. 480 Activity of Cyp3A in Mothers and Their Newborns Using 4B-Hydroxycholesterol as a Marker
84. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).
85. Clinical relevance with focus on psychotropic drugs.
86. Voriconazole Increases while Itraconazole Decreases Plasma Meloxicam Concentrations
87. Carbamazepine metabolism in man - Influence of auto and hetero-induction on some different oxidative pathways
88. PHARMACOKINETICS OF CARBAMAZEPINE-10, 11-EPOXIDE IN HEALTHY VOLUNTEERS
89. Moving toward genetic profiling in patient care: the scope and rationale of pharmacogenetic/ecogenetic investigation.
90. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients.
91. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
92. CYP2D6 genotype and antipsychotic-induced extrapyramidal side-effects in schizophrenic patients.
93. Different myrosine and idioblast distribution in Arabidopsis and Brassica napus
94. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism.
95. Effects of loong-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders.
96. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva and urine.
97. Omeprazole and CYP2C19 polymorphism : Effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
98. The effects of long-term omeprazole therapy on gastrin, pepsinogen I, and chromogranin A concentrations are related to CYP2C19 polymorphism.
99. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists
100. P.2.a.028 Monoamine metabolites level in CSF are related to the 5-HTT gene polymorphism in treatment-resistant depression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.